Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano
{"title":"Neoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report.","authors":"Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano","doi":"10.1080/1750743X.2025.2535941","DOIUrl":null,"url":null,"abstract":"<p><p>Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent years, expression of programmed death ligand 1 (PD-L1) has been investigated in mesothelioma with implications for targeted therapy. In this case report, we present a patient with solitary isolated peritoneal mesothelioma of the right flank with abdominal and chest wall involvement and high PD-L1 positivity. The patient demonstrated a remarkable metabolic response to neoadjuvant immunotherapy using nivolumab and ipilimumab, which was followed by a successful surgical resection. Pathological evaluation revealed a complete pathological response, highlighting the effectiveness of the treatment strategy.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2535941","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent years, expression of programmed death ligand 1 (PD-L1) has been investigated in mesothelioma with implications for targeted therapy. In this case report, we present a patient with solitary isolated peritoneal mesothelioma of the right flank with abdominal and chest wall involvement and high PD-L1 positivity. The patient demonstrated a remarkable metabolic response to neoadjuvant immunotherapy using nivolumab and ipilimumab, which was followed by a successful surgical resection. Pathological evaluation revealed a complete pathological response, highlighting the effectiveness of the treatment strategy.
期刊介绍:
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.